

NEOPHOTONICS CORP
Form 10-Q/A
April 09, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-35061

NeoPhotonics Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

94-3253730
(I.R.S. Employer
Identification No.)

2911 Zanker Road

San Jose, California 95134

(Address of principal executive offices, zip code)

(408) 232-9200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 ("Exchange Act") during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of July 31, 2013, there were 31,255,741 shares of the registrant's Common Stock outstanding.

Explanatory Note

NeoPhotonics Corporation (the “Company”), is filing this Amendment No. 1 (“Amendment”) to its Quarterly Report on Form 10-Q to restate and amend the Company’s previously issued and unaudited interim financial statements and related financial information as of June 30, 2013 and for the three and six months ended June 30, 2013, which was originally filed with the Securities and Exchange Commission on August 8, 2013.

As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on November 14, 2013, the Company determined that its unaudited condensed consolidated financial statements for the six months ended June 30, 2013 contained an error related to its accounting for a real estate registration tax which was incorrectly reflected as a component of the property, plant and equipment acquired as part of the purchase of NeoPhotonics Semiconductor (formerly the Optical Component Unit of LAPIS Semiconductor). In addition, the Company has made other corrections related to the purchase of NeoPhotonics Semiconductor, classification of certain amounts and other corrections, all of which were discovered during the close of its September 30, 2013 accounting records. For further information regarding the restatement, see Note 2 of the Notes to the Condensed Consolidated Financial Statements.

Because of the corrections described above, management re-evaluated the Company’s control environment and concluded that additional material weaknesses existed at June 30, 2013 as more fully described in Item 4 “Controls and Procedures” in this Amendment.

Consistent with the information described above, the Company has revised the following items in this Amendment:

Part I

Item 1 – Condensed Consolidated Financial Statements

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 4 – Controls and Procedures

Part II

Item 1A- Risk Factors

Additionally, in this Amendment, the Company is including currently dated certifications from the Company’s Principal Executive Officer and Principal Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002 in Exhibits 31.1 and 31.2 and a currently dated certification from the Company’s Principal Executive Officer and Principal Financial Officer as required by Section 906 of the Sarbanes-Oxley Act of 2002 in Exhibit 32.1.

Except to the extent described above and set forth herein, the items and other disclosures in the Form 10-Q initially filed on August 8, 2013 are unchanged and this Amendment does not reflect any events that have occurred after the initial Form 10-Q was filed. Accordingly, this Amendment should be read in conjunction with the Company’s initial Form 10-Q and the Company’s subsequent filings with the United States Securities and Exchange Commission.

In light of the restatement, readers should not rely on the Company’s previously filed financial statements as of and for the three and six month periods ended June 30, 2013.

NEOPHOTONICS CORPORATION

For the Quarter Ended June 30, 2013

Table of Contents

	Page
<u>Part I. Financial Information</u>	
Item 1. <u>Condensed Consolidated Financial Statements</u>	4
<u>Condensed Consolidated Balance Sheets as of June 30, 2013 (Restated and Revised) and December 31, 2012 (Revised)</u>	4
<u>Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2013 (Restated and Revised) and 2012</u>	5
<u>Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2013 (Restated and Revised) and 2012</u>	6
<u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2013 (Restated and Revised) and 2012</u>	7
<u>Notes to Condensed Consolidated Financial Statements</u>	8
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	33
Item 4. <u>Controls and Procedures</u>	43
<u>Part II. Other Information</u>	
Item 1A. <u>Risk Factors</u>	46
Item 6. <u>Exhibits</u>	71
<u>Signatures</u>	72

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NEOPHOTONICS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	As of June 30, 2013 Restated and Revised, see Notes 2 and 7	December 31, 2012 Revised, see Note 2
(In thousands, except share and per share data)		
ASSETS		
Current assets:		
Cash and cash equivalents	\$37,558	\$ 36,940
Short-term investments	36,874	64,301
Restricted cash	1,813	2,626
Accounts receivable, net of allowance for doubtful accounts	72,998	70,354
Inventories	58,227	43,793
Prepaid expenses and other current assets	8,863	7,630
Total current assets	216,333	225,644
Long-term investments	355	188
Property, plant and equipment, net	70,761	54,440
Other intangible assets, net	17,362	14,213
Other long-term assets	1,318	1,147
Total assets	\$306,129	\$ 295,632
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$43,894	\$ 36,308
Notes payable	9,041	12,003
Current portion of long-term debt	8,785	5,000
Accrued and other current liabilities	20,530	19,959
Total current liabilities	82,250	73,270
Long-term debt, net of current portion	28,070	17,167
Deferred income tax liabilities	664	653
Other noncurrent liabilities	7,882	1,862
Total liabilities	118,866	92,952

Commitments and contingencies (Note 10)

Stockholders' equity:

Preferred stock, \$0.0025 par value

At June 30, 2013 and December 31, 2012: 10,000,000 shares authorized, no shares

issued or outstanding

— —

Common stock, \$0.0025 par value

At June 30, 2013: 100,000,000 shares authorized, 30,971,280 shares issued and

outstanding; At December 31, 2012: 100,000,000 shares authorized, 30,546,155 shares

issued and outstanding

77 76

Additional paid-in capital

443,157 438,858

Accumulated other comprehensive income

12,636 11,829

Accumulated deficit

(268,607) (248,083)

Total stockholders' equity

187,263 202,680

Total liabilities and stockholders' equity

\$306,129 \$ 295,632

See accompanying Notes to Condensed Consolidated Financial Statements.

NEOPHOTONICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended		Six Months Ended June 30,	
	June 30, 2013		2013	2012
	Restated and Revised, see Notes 2 and 7	2012	Restated and Revised, see Notes 2 and 7	2012
(In thousands, except share and per share data)				
Revenue	\$74,990	\$63,025	\$131,053	\$117,248
Cost of goods sold	59,389	47,837	103,695	90,654
Gross profit	15,601	15,188	27,358	26,594
Operating expenses:				
Research and development	11,087	9,322	20,794	19,860
Sales and marketing	3,349	3,406	6,935	6,429
General and administrative	7,889	6,409	13,273	13,140
Acquisition-related transaction costs	681	312	5,191	706
Amortization of purchased intangible assets	426	321	747	675
Adjustment to fair value of contingent consideration	—	(1,303)	—	604
Total operating expenses	23,432	18,467	46,940	41,414
Loss from operations	(7,831)	(3,279)	(19,582)	(14,820)
Interest income	72	145	203	277
Interest expense	(342)	(145)	(505)	(299)
Other expense, net	(273)	—	(547)	(275)
Total interest and other expense, net	(543)	—	(849)	(297)
Loss before income taxes	(8,374)	(3,279)	(20,431)	(15,117)
Benefit (provision) for income taxes	90	(377)	(93)	(317)
Loss from continuing operations	(8,284)	(3,656)	(20,524)	(15,434)
Income from discontinued operations, net of tax (including gain on disposal of \$636, net of tax, for the six months ended June 30, 2012)	—	—	—	170
Net loss	\$(8,284)	\$(3,656)	\$(20,524)	\$(15,264)
Basic and diluted net loss per share attributable to NeoPhotonics Corporation common stockholders:				
Continuing operations	\$(0.27)	\$(0.13)	\$(0.67)	\$(0.58)
Discontinued operations	\$—	\$—	\$—	\$0.01
Net loss	\$(0.27)	\$(0.13)	\$(0.67)	\$(0.57)
Weighted average shares used to compute net loss per share attributable to NeoPhotonics Corporation common stockholders:				
Basic and diluted	30,779,730	28,402,929	30,677,449	26,636,807

See accompanying Notes to Condensed Consolidated Financial Statements.

NEOPHOTONICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

	Three Months Ended June 30, 2013		Six Months Ended June 30, 2013	
	Restated and Revised, see Notes 2 and 7		Restated and Revised, see Notes 2 and 7	
(In thousands)	2012	2012	2012	2012
Net loss	\$ (8,284)	\$ (3,656)	\$ (20,524)	\$ (15,264)
Foreign currency translation adjustments	689	(472)	861	(347)
Unrealized gains (losses) on investments, net of tax of \$0	(35)	(60)	(54)	236
Comprehensive loss	\$ (7,630)	\$ (4,188)	\$ (19,717)	\$ (15,375)

See accompanying Notes to Condensed Consolidated Financial Statements.

NEOPHOTONICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended June 30, 2013	
	Restated and Revised, see Notes 2 and 7	2012
(In thousands)		
Cash flows from operating activities		
Net loss	\$ (20,524)	\$ (15,264)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	9,512	9,827
Stock-based compensation expense	2,675	2,153
Deferred taxes	(6)	387
Amortization of premiums and discounts on investments	669	386
Gain on sale of discontinued operations	—	(750)
Allowance for doubtful accounts	(144)	93
Write-down of inventories	849	2,931
Others	465	82
Change in assets and liabilities, net of effects of acquisitions:		
Accounts receivable	(1,766)	(6,771)
Inventories	(1,577)	(8,081)
Prepaid expenses and other current assets	47	(1,303)
Accounts payable	2,308	3,763
Acquisition-related transaction costs	3,282	—
Accrued and other liabilities	104	733
Net cash used in operating activities	(4,106)	(11,814)
Cash flows from investing activities		
Purchase of property, plant and equipment	(10,545)	(4,965)
Proceeds from disposition of property, plant and equipment	92	—
Purchase of marketable securities	(48,771)	(112,773)
Proceeds from sale of marketable securities	35,247	53,294
Proceeds from maturity of securities	40,255	29,532
Decrease in restricted cash	859	647
Acquisition, net of cash acquired	(14,979)	—
Proceeds received on sale of discontinued operations, net of tax	—	1,825
Net cash provided by (used in) investing activities	2,158	(32,440)

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

Cash flows from financing activities		
Proceeds from issuance of common stock, net of issuance costs	—	39,636
Proceeds from exercise of stock options	572	188
Proceeds from issuance of stock under ESPP	1,162	923
Proceeds from bank loans	26,443	—
Repayment of bank loans	(22,360)	(2,500)
Proceeds from issuance of notes payable	9,471	12,759
Repayment of notes payable	(12,661)	(16,064)
Net cash provided by financing activities	2,627	34,942
Effect of exchange rates on cash and cash equivalents	(61)	56
Net increase (decrease) in cash and cash equivalents	618	(9,256)
Cash and cash equivalents at the beginning of the period	36,940	32,485
Cash and cash equivalents at the end of the period	\$ 37,558	\$ 23,229
Supplemental disclosure of noncash investing and financing activities:		
Issuance of notes to the seller of acquired business	\$ 11,130	\$ —

See accompanying Notes to Condensed Consolidated Financial Statements

NeoPhotonics Corporation

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1. Basis of presentation

The condensed consolidated financial statements of NeoPhotonics Corporation (“NeoPhotonics” or the “Company”) as of June 30, 2013 and December 31, 2012 and for the three and six months ended June 30, 2013 and 2012, have been prepared in accordance with the instructions on Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In accordance with those rules and regulations, the Company has omitted certain information and notes normally provided in the Company’s annual consolidated financial statements. In the opinion of management, the condensed consolidated financial statements contain all adjustments, consisting only of normal recurring items, except as otherwise noted, necessary for the fair presentation of the Company’s financial position and results of operations for the interim periods. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). These condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The results of operations for the three and six months ended June 30, 2013 are not necessarily indicative of the results expected for the entire fiscal year. For purposes of these Notes to Condensed Consolidated Financial Statements, amounts have been restated and revised to give effect to the matters described in Note 2.

Consolidation

The condensed consolidated financial statements are prepared in accordance with U.S. GAAP and include the consolidated accounts of the Company and its majority owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenue and expenses during the reporting period. Significant estimates made by management include: the fair values of identifiable assets acquired and liabilities assumed in business combinations; the useful lives of property, plant and equipment and intangible assets as well as future cash flows to be generated by those assets; allowances for doubtful accounts; valuation allowances for deferred tax assets; write off of excess and obsolete inventories and the valuations of stock-based compensation, among others. Actual results could differ from these estimates.

Business Combinations—Acquisition Accounting

Under the acquisition method of accounting, the Company allocates the purchase price of acquired companies to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values. The Company records the excess of purchase price over the aggregate fair values of the tangible and identifiable intangible assets as goodwill. The Company determines the fair values of assets acquired and liabilities assumed. To establish

fair value, the Company measures the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants. The measurement assumes the highest and best use of the asset by the market participants that would maximize the value of the asset or the group of assets within which the asset would be used at the measurement date, even if the intended use of the asset is different.

The Company estimates the economic lives of certain acquired assets and these lives are used to calculate depreciation and amortization expenses. The Company estimates the future cash flows to be derived from such assets, and these estimates are used to determine the fair value of the assets. If any of these estimates change, depreciation or amortization expenses could be changed and/or the value of our intangible assets could be impaired.

Acquisition related costs, including real estate transaction taxes, finder's fees, advisory, legal, accounting, valuation and other professional or consulting fees are accounted for as expenses in the periods in which the costs are incurred or the services are received.

Note 2. Restatement and Revision of unaudited condensed consolidated financial statements

The Company has restated and revised its June 30, 2013 unaudited condensed consolidated financial statements as described below.

The effects of the restatement and revisions on the condensed consolidated balance sheet as of June 30, 2013 are summarized in the following table:

June 30, 2013 (In thousands, except per share data)					
	Previously Reported	Corrections	Penalty Payment Derivative	Revision for Measurement Period Adjustments	Restated and Revised
ASSETS					
Current assets:					
Cash and cash equivalents	\$37,857	\$ (299)	\$ —	\$ —	\$37,558
Short-term investments	36,874	—	—	—	36,874
Restricted cash	1,813	—	—	—	1,813
Accounts receivable, net of allowance for doubtful accounts	72,998	—	—	—	72,998
Inventories	64,164	(15)	—	(5,922)	58,227
Prepaid expenses and other current assets	6,684	306	—	1,873	8,863
Total current assets	220,390	(8)	—	(4,049)	216,333
Long-term investments	355	—	—	—	355
Property, plant and equipment, net	65,886	2,045	—	2,830	70,761
Goodwill	2,084	(2,084)	—	—	—
Other intangible assets, net	15,926	(62)	—	1,498	17,362
Other long-term assets	3,586	(2,274)	—	6	1,318
Total assets	\$308,227	\$ (2,383)	\$ —	\$ 285	\$306,129
LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY					
Current liabilities:					
Accounts payable	\$44,115	\$ (221)	\$ —	\$ —	\$43,894
Notes payable	9,041	—	—	—	9,041
Current portion of long-term debt	10,535	(1,750)	—	—	8,785
Accrued and other current liabilities	19,708	811	—	11	20,530
Total current liabilities	83,399	(1,160)	—	11	82,250
Long-term debt, net of current portion	26,320	1,750	—	—	28,070
Deferred income tax liabilities	664	—	—	—	664
Other noncurrent liabilities	10,030	(2,293)	138	7	7,882
Total liabilities	120,413	(1,703)	138	18	118,866
Redeemable common stock	5,000	—	(5,000)	—	—

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

Stockholders' equity:

Preferred stock, \$0.0025 par value	—	—	—	—	—
Common stock, \$0.0025 par value	77	—	—	—	77
Additional paid-in capital	438,295	—	4,862	—	443,157
Accumulated other comprehensive income	12,521	74	—	41	12,636
Accumulated deficit	(268,079)	(754)	—	226	(268,607)
Total stockholders' equity	182,814	(680)	4,862	267	187,263
Total liabilities, redeemable common stock and stockholders' equity	\$308,227	\$ (2,383)	\$ —	\$ 285	\$306,129

9

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

The effects of the restatement and revisions on the condensed consolidated statement of operations for the three months ended June 30, 2013 are summarized in the following table:

Three Months Ended June 30, 2013 (In thousands, except share and per share information)				
	Previously Reported	Corrections	Revision for Measurement Period Adjustments	Restated and Revised
Revenue	\$74,990	\$ —	\$ —	\$74,990
Cost of goods sold	59,805	1	(417)	59,389
Gross profit	15,185	(1)	417	15,601
Operating expenses:				
Research and development	11,311	(245)	21	11,087
Sales and marketing	3,369	(20)	—	3,349
General and administrative	8,470	21	79	8,570
Amortization of purchased intangible assets	362	—	64	426
Total operating expenses	23,512	(244)	164	23,432
Loss from operations	(8,327)	243	253	(7,831)
Interest income	72	—	—	72
Interest expense	(342)	—	—	(342)
Other expense, net	(273)	—	—	(273)
Total interest and other expense, net	(543)	—	—	(543)
Loss before income taxes	(8,870)	243	253	(8,374)
Provision for income taxes	(662)	—	752	90
Net loss	\$(9,532)	\$ 243	\$ 1,005	\$(8,284)
Basic and diluted net loss per share:				
Net loss	\$(0.31)			\$(0.27)

Weighted average shares used to compute basic and diluted

net loss per share 30,779,730 30,779,730

The effects of the restatement and revision on the condensed consolidated statement of comprehensive loss for the three months ended June 30, 2013 are summarized in the following table:

Three Months Ended June 30, 2013 (In thousands)				
	Previously Reported	Corrections	Revision for Measurement Period Adjustments	Restated and Revised

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

Net loss	\$(9,532)	\$ 243	\$ 1,005	\$(8,284)
Foreign currency translation adjustments	587	61	41	689
Unrealized loss on investments, net of tax of \$0	(35)	—	—	(35)
Comprehensive loss	\$(8,980)	\$ 304	\$ 1,046	\$(7,630)

10

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

The effects of the restatement and revision on the condensed consolidated statement of operations for the six months ended June 30, 2013 are summarized in the following table:

	Six Months Ended June 30, 2013 (In thousands, except share and per share information)			
	Previously Reported	Corrections	Revision for Measurement Period Adjustments	Restated and Revised
Revenue	\$ 131,053	\$ —	\$ —	\$ 131,053
Cost of goods sold	104,138	(26)	(417)	103,695
Gross profit	26,915	26	417	27,358
Operating expenses:				
Research and development	21,018	(245)	21	20,794
Sales and marketing	6,955	(20)	—	6,935
General and administrative	17,340	1,045	79	18,464
Amortization of purchased intangible assets	683	—	64	747
Total operating expenses	45,996	780	164	46,940
Loss from operations	(19,081)	(754)	253	(19,582)
Interest income	203	—	—	203
Interest expense	(505)	—	—	(505)
Other expense, net	(547)	—	—	(547)
Total interest and other expense, net	(849)	—	—	(849)
Loss before income taxes	(19,930)	(754)	253	(20,431)
Provision for income taxes	(66)	—	(27)	(93)
Net loss	\$(19,996)	\$(754)	\$ 226	\$(20,524)
Basic and diluted net loss per share:				
Net loss	\$(0.65)			\$(0.67)

Weighted average shares used to compute basic and diluted net loss per share

30,677,449

30,677,449

The effects of the restatement and revision on the condensed consolidated statement of comprehensive loss for the six months ended June 30, 2013 are summarized in the following table:

	Six Months Ended June 30, 2013 (In thousands)		
	Previously Reported	Corrections	Revision for Measurement Period

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

			Adjustments	
Net loss	\$(19,996)	\$ (754)	\$ 226	\$(20,524)
Foreign currency translation adjustments	747	73	41	861
Unrealized loss on investments, net of tax of \$0	(54)	—	—	(54)
Comprehensive loss	\$(19,303)	\$ (681)	\$ 267	\$(19,717)

11

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

The effects of the restatement and revisions on the condensed consolidated statement of cash flows for the six months ended June 30, 2013 are summarized in the following table:

	Six Months Ended June 30, 2013 (In thousands)			Restated and Revised
	Previously Reported	Corrections	Revision for Measurement Period Adjustments	
Cash flows from operating activities				
Net loss	\$ (19,996)	\$ (754)	\$ 226	\$ (20,524)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	9,769	(546)	289	9,512
Stock-based compensation expense	2,675	—	—	2,675
Deferred taxes	(6)	—	—	(6)
Amortization of premiums and discounts on investments	669	—	—	669
Allowance for doubtful accounts	(144)	—	—	(144)
Write-down of inventories	831	—	18	849
Others	471	—	(6)	465
Change in assets and liabilities, net of effects of acquisitions:				
Accounts receivable	(1,766)	—	—	(1,766)
Inventories	(838)	(187)	(552)	(1,577)
Prepaid expenses and other current assets	(48)	97	(2)	47
Accounts payable	4,346	(2,038)	—	2,308
Acquisition-related transaction costs	2,524	758	—	3,282
Accrued and other liabilities	(2,590)	2,667	27	104
Net cash used in operating activities	(4,103)	(3)	—	(4,106)
Cash flows from investing activities				
Purchase of property, plant and equipment	(10,300)	(245)	—	(10,545)
Proceeds from disposition of property, plant and equipment	92	—	—	92
Purchase of marketable securities	(48,771)	—	—	(48,771)
Proceeds from sale of marketable securities	35,247	—	—	35,247
Proceeds from maturity of securities	40,255	—	—	40,255
Decrease in restricted cash	859	—	—	859
Acquisition, net of cash acquired	(14,928)	(51)	—	(14,979)
Net cash provided by (used in) investing activities	2,454	(296)	—	2,158
Cash flows from financing activities				
Proceeds from exercise of stock options	572	—	—	572
Proceeds from issuance of stock under ESPP	1,162	—	—	1,162
Proceeds from bank loans	40,000	(13,557)	—	26,443
Repayment of bank loans	(35,917)	13,557	—	(22,360)
Proceeds from issuance of notes payable	9,471	—	—	9,471

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

Repayment of notes payable	(12,661)	—	—	(12,661)
Net cash provided by financing activities	2,627	—	—	2,627
Effect of exchange rates on cash and cash equivalents	(61)	—	—	(61)
Net increase (decrease) in cash and cash equivalents	917	(299)	—	618
Cash and cash equivalents at the beginning of the period	36,940	—	—	36,940
Cash and cash equivalents at the end of the period	\$37,857	\$ (299)	\$ —	\$37,558

12

Corrections

Subsequent to the initial filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2013, the Company determined that its condensed consolidated financial statements as of June 30, 2013 and for the three and six months then ended contained errors requiring restatement. As further described below, the restatement reflects corrections related to the purchase of NeoPhotonics Semiconductor (formerly the Optical Component Unit of LAPIS Semiconductor), classification of certain amounts and other corrections. The restatement adjustments include consideration of the related income tax effect.

Purchase Accounting Corrections

The Company has concluded that a real estate registration tax in the amount of \$0.5 million was incorrectly allocated to property, plant and equipment acquired as part of the purchase of NeoPhotonics Semiconductor and should have been expensed. Additionally, the Company identified (i) real estate acquisition tax in the amount of \$0.8 million that should have been accrued as an acquisition cost in the six months ended June 30, 2013, (ii) a correction to the estimated fair value of property and equipment that increased property and equipment and reduced goodwill by \$2.1 million, (iii) unrecorded liabilities related to warranty obligation adjustments that were omitted at March 31, 2013, resulting in an understatement of current liabilities of \$0.1 million at June 30, 2013 and (iv) an overstatement of cost of goods sold of \$0.1 million and an overstatement of research and development expenses of \$0.2 million for the three and six months ended June 30, 2013. The Company also misclassified payments to Lapis of \$0.9 million as cash used in operating activities rather than cash used in investing activities in the statement of cash flows for the six months ended June 30, 2013.

Classification Corrections

The Company has concluded that it incorrectly separately classified a long-term asset related to the pension obligation assumed in the purchase of NeoPhotonics Semiconductor in the amount of \$2.1 million that should instead have been netted against the long-term pension liability at June 30, 2013. Additionally, the Company (i) overstated the current portion of long-term debt by \$1.8 million at June 30, 2013, (ii) misclassified \$0.3 million of cash held by a service provider as cash and cash equivalents at June 30, 2013 that should have been classified as a prepaid and other asset, (iii) misclassified certain costs between cost of goods sold and operating expenses of \$0.1 million and \$0.3 million in the three and six months ended June 30, 2013, respectively, and (iv) misclassified \$1.7 million between the change in accounts payable and the change in accrued and other liabilities within operating activities and overstated both proceeds from and repayment of bank loans by \$13.6 million within financing activities in its condensed consolidated statement of cash flows for the six months ended June 30, 2013.

Other Corrections

The Company concluded that it had incorrectly recorded amounts related to an asset retirement obligation resulting in an overstatement of other long-term liabilities of \$0.3 million at June 30, 2013 and had incorrectly recorded certain purchased software maintenance contracts which resulted in an overstatement of property, plant and equipment of \$0.2 million at June 30, 2013. The Company also overstated amounts payable to two vendors, resulting in an overstatement of previously reported cost of goods sold and operating expenses by \$0.2 million and \$0.3 million for the three and six months ended June 30, 2013, respectively and understated an accrued expense, resulting in an understatement of operating expenses by \$0.1 million for the three and six months ended June 30, 2013.

Penalty Payment Derivative

As further described in Note 11, the Company may be required to pay a \$5.0 million penalty if it does not achieve certain performance obligations agreed to in connection with the sale of its common stock in a private placement transaction on April 27, 2012. The penalty payment was originally classified outside of equity as redeemable common stock at December 31, 2012 and June 30, 2013 since, while the Company intends to meet its performance obligations, it determined the ability to satisfy some of the obligations may be outside of the Company's control. The Company has since determined that the \$5.0 million penalty payment is an embedded derivative instrument, with the underlying being the performance or nonperformance of meeting its performance obligations by the deadline, and has thus classified \$4.9 million of the \$5.0 million to additional paid-in capital and the remaining \$0.1 million, representing the estimated fair value of the penalty payment derivative, to other noncurrent liabilities at June 30, 2013 and December 31, 2012. The effect on the Company's balance sheet at December 31, 2012 for this matter was as follows:

(in thousands)	December 31, 2012	
	Previously Reported	As Revised
Other noncurrent liabilities	\$ 1,724	\$ 1,862
Redeemable common stock	5,000	—
Additional paid-in capital	433,996	438,858

Revision for Purchase Price Allocation Measurement Period Adjustments

With the reissuance of these condensed consolidated financial statements, the Company has revised its June 30, 2013 condensed consolidated balance sheet and its condensed consolidated statements for the three and six months ended June 30, 2013 from amounts previously reported to reflect measurement period adjustments in the estimated fair value of inventory, property and equipment and other tangible and intangible assets acquired in the purchase of NeoPhotonics Semiconductor. The changes in estimated fair value resulted from additional information obtained subsequent to the Company's initial acquisition accounting. The Company also recorded an initial valuation allowance against the NeoPhotonics Semiconductor deferred tax assets as a measurement period adjustment in the three months ended March 31, 2013, rather than during the three months ended June 30, 2013 due to additional information received subsequent to the Company's initial acquisition accounting.

Notes to Condensed Consolidated Financial Statements

In addition to the above adjustments, there were computational errors in deriving certain footnote amounts included within the Company's initial Quarterly Report on Form 10-Q. Those amounts have been corrected herein.

Note 3. Significant accounting policies

Except as described in Note 2, there have been no changes in the Company's significant accounting policies for the six months ended June 30, 2013, as compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Recent accounting pronouncements

In February 2013, the Financial Accounting Standard Board (“FASB”) issued amendments to the FASB Accounting Standard Codification to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments require new disclosures for items reclassified out of accumulated other comprehensive income (“AOCI”), including (1) changes in AOCI balances by component and (2) significant items reclassified out of AOCI. The guidance does not amend any existing requirements for reporting net income or OCI in the financial statements. As this guidance only requires expanded disclosures, the adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In March 2013, the FASB issued amendments to the FASB Accounting Standard Codification, which indicates that the entire amount of a cumulative translation adjustment related to an entity’s investment in a foreign entity should be released when there has been a (i) sale of a subsidiary or group of net assets within a foreign entity and the sale represents the substantially complete liquidation of the investment in the foreign entity, (ii) loss of a controlling financial interest in an investment in a foreign entity, or (iii) step acquisition for a foreign entity. The amendments are effective prospectively for fiscal years beginning after December 15, 2013. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact to the Company’s consolidated financial statements.

In July 2013, the FASB issued amendments to the FSAB Accounting Standard Codification on Income Taxes, to improve the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is expected to reduce diversity in practice and is expected to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exists. This guidance is effective for reporting periods beginning after December 15, 2013. The adoption of this guidance is not expected to have a material impact to the Company's consolidated financial statements.

Note 4. Discontinued operations

In the fourth quarter of 2011, the Company initiated a plan to sell a component of its business, Broadband, a subsidiary in China. The Company decided to sell Broadband because the nature of its operations was different than the core technology and strategy of the Company. On January 11, 2012, the Company entered into a purchase agreement with Guangdong Rainbow Electronic Ltd. (Rainbow) to dispose of its 100% equity interest in Broadband for a total cash consideration of RMB 13.0 million (\$2.1 million). The transaction closed on March 13, 2012. The Company recognized a gain of \$0.6 million on the sale of Broadband, representing the difference between the consideration received and the net assets transferred to Rainbow, net of tax. The gain was included in income from discontinued operations, net of tax in the statement of operations for the six months ended June 30, 2012.

The results of operations associated with Broadband are presented as discontinued operations in the Company's consolidated statements of operations for the three and six months ended June 30, 2013 and 2012. Revenue and the components of net income related to the discontinued operations for all periods were as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Revenue	\$ —	\$ —	\$ —	\$ 590
Income from discontinued operations before income taxes	—	—	—	284
Provision for income taxes	—	—	—	(114)
Income from discontinued operations	\$ —	\$ —	\$ —	\$ 170

Note 5. Cash equivalents and investments and fair value disclosures

Cash equivalents and investments

The following table summarizes the Company's unrealized gains and losses related to the cash equivalents and investments in marketable securities designated as available-for-sale (in thousands):

As of June 30, 2013

As of December 31, 2012

Edgar Filing: NEOPHOTONICS CORP - Form 10-Q/A

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Cash and cash equivalents								
Money market funds	\$11	\$ —	\$ —	\$11	\$11	\$ —	\$ —	\$11
Short-term investments								
Money market funds	13,098	—	—	13,098	7,259	—	—	7,259
Corporate bonds	13,657	20	(3)	13,674	23,151	43	(1)	23,193
U.S. federal agencies	3,060	1	—	3,061	27,241	10	—	27,251
Foreign bonds and notes	5,245	5	(10)	5,240	4,682	14	—	4,696
Municipal obligations	1,801	—	—	1,801	1,902	—	—	1,902
Total investments in short-term investments	36,861	26	(13)	36,874	64,235	67	(1)	64,301
Total investments	\$36,872	\$ 26	\$ (13)	\$36,885 ⁽¹⁾	\$64,246	\$ 67	\$ (1)	\$64,312 ⁽¹⁾

⁽¹⁾Interest income receivable included in total investments balance was \$0.2 million and \$0.4 million at June 30, 2013 and December 31, 2012, respectively.

As of June 30, 2013 and December 31, 2012, maturities of short-term investments are as follows (in thousands):

	June 30, 2013	December 31, 2012
Less than 1 year	\$33,090	\$ 51,861
Due in 1 to 2 years	—	10,550
Due in 2 to 5 years	1,994	—
Due after 5 years	1,801	1,901
Total	\$36,885	\$ 64,312

The Company may sell its security investments in the future to fund future operation needs. As a result, the Company recorded all its marketable securities in short-term investment as of June 30, 2013 and December 31, 2012, regardless of the contractual maturity date of the securities.

Realized gains and losses on the sale of marketable securities during the three and six months ended June 30, 2013 and 2012 were immaterial. The Company did not recognize any impairment losses on its marketable securities during the three and six months ended June 30, 2013 and 2012. As of June 30, 2013, the Company did not have any investments in marketable securities that were in an unrealized loss position for a period in excess of 12 months.

Fair value disclosures

The following table sets forth the fair value of the Company's financial assets as of the dates presented (in thousands):

As of June 30, 2013				As of December 31, 2012		
Level 1		Level 3	Total	Level 1		Level 3
1	2	Level 3	Total	1	2	Level 3